9 completed, 5 active not recruiting, 1 recruiting, 1 terminated. 15 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 9, Active not recruiting 5, Withdrawn 1 |
| Phase 2 | 8 | Completed 4, Active not recruiting 2, Recruiting 1, Terminated 1 |
Follow rocakinogene sifuplasmid: new trials by email Literature Review of rocakinogene sifuplasmid trials Research Report on rocakinogene sifuplasmid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012 - HCC | Phase 2 | Recruiting | Geneos Therapeutics | 90 | 2026-09-01 | 2026-09-23 |
| Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers INO-4800, INO-9112, CELLECTRA® 2000 - Coronavirus Infection | Phase 1 | Withdrawn | Inovio Pharmaceuticals | 2022-10-01 | 2022-11-17 | |
| INO 5401 Vaccination in BRCA1/2 Mutation Carriers INO-5401, INO-9012, Cellectra 2000 - BRCA1/2 Mutation | Phase 1 | Active not recruiting | University of Pennsylvania | 44 | 2021-04-20 | 2026-10-21 |
| Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics, CELLECTRA®2000 EP Device supplied by Geneos Therapeutics, Plasmid encoded IL-12 - Glioblastoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 9 | 2020-07-14 | 2026-10-23 |
| GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC GNOS-PV02, INO-9012, Pembrolizumab - HCC | Phase 1 / Phase 2 | Active not recruiting | Geneos Therapeutics | 36 | 2020-03-01 | 2026-09-24 |
| DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab - Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | Phase 2 | Terminated | M.D. Anderson Cancer Center | 41 | 2018-11-14 | 2024-07-09 |
| Therapeutic Vaccination in Treated HIV Disease PENNVAX-GP, INO-6145, INO-9012 - HIV-1-infection | Phase 1 / Phase 2 | Completed | Steven Deeks | 56 | 2018-08-01 | 2023-05-31 |
| INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma INO-5401, INO-9012, Atezolizumab - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 35 | 2018-07-24 | 2026-09-02 |
| INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) INO-5401, INO-9012, Cemiplimab - Glioblastoma | Phase 1 / Phase 2 | Active not recruiting | Inovio Pharmaceuticals | 52 | 2018-05-31 | 2026-10-22 |
| DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis - Chronic Hepatitis, Hepatitis C Infection | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2016-06-06 | 2026-09-11 |
| Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer 2mg INO-5150 and electroporation device CELLECTRA®-5P, 8.5mg INO-5150 and electroporation device CELLECTRA®-5P, 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P - Prostate Cancer | Phase 1 | Completed | Inovio Pharmaceuticals | 62 | 2015-07-01 | 2017-12-26 |
| Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers INO-4201, INO-4202, INO-4212 - Ebola Vaccine | Phase 1 | Completed | Inovio Pharmaceuticals | 240 | 2015-05-01 | 2019-06-28 |
| Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment - Hepatitis B | Phase 1 | Completed | Inovio Pharmaceuticals | 90 | 2015-01-12 | 2019-10-15 |
| hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse INO-1400, INO-9012, INO-1401 - Breast Cancer, Lung Cancer | Phase 1 | Completed | Inovio Pharmaceuticals | 93 | 2014-12-01 | 2018-11-19 |
| Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma INO-3112, CELLECTRA™-5P - Head and Neck Squamous Cell Cancer | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 22 | 2014-08-13 | 2021-01-22 |
| A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer INO-3112, CELLECTRA™-5P - Cervical Cancer | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 10 | 2014-06-06 | 2021-02-21 |
| Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies INO-3106, INO-9012 - Aerodigestive Precancerous Lesions and Malignancies | Phase 1 | Completed | Inovio Pharmaceuticals | 3 | 2014-05-01 | 2018-11-16 |
Carcinoma, Hepatocellular (2) · Glioblastoma (2) · Neoplasms (2) · Uterine Cervical Neoplasms (2) · Anal Canal Carcinoma (1) · Anus Neoplasms (1) · Breast Neoplasms (1) · COVID-19 (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Coronavirus Infections (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Hemorrhagic Fever, Ebola (1)
Inovio Pharmaceuticals (10) · Geneos Therapeutics (2) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Steven Deeks (1) · University of Pennsylvania (1) · Washington University School of Medicine (1)
United States (16) · New Zealand (3) · Australia (1) · Hong Kong (1) · Philippines (1) · Puerto Rico (1) · Singapore (1) · Taiwan (1) · Thailand (1)
Jeffrey Skolnik, MD (5) · Anthony Shields, MD (1) · Ashish Chintakuntlawar, MBBS, PhD (1) · Autumn McRee, MD (1) · Ildi Csiki, MD, PH.D. (1) · Jeffrey M Jacobson (1) · Jennifer Johnson, MD (1) · Jose Suaya, MD (1) · Michael M Frumovitz (1) · Nathan Bahary, MD (1) · Robert Vonderheide, MD, PhD (1) · Scott White, MD (1) · ShuPing Yang, MD, PhD (1) · Steven Deeks, MD (1) · Susan Domchek, MD (1)
PMID 30891607, PMID 38584166, PMID 38991631, PMID 42120910
N01CN00042 (1), P30CA015083 (1), R01NS112712 (1), U01AI131296 (1)